UBS maintains Encompass Health at Buy, raises price target to $165 from $155
Less than 1 min read
UBS maintained Encompass Health at Buy and raised its price target to $165 from $155, a 6.5% increase.
The price target implies an upside of 21.4% from the Oct 30 close of $135.90.
Recent analyst actions on Encompass Health
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 30 | TD Cowen | Maintains | Buy | $150 |
| Oct 30 | Truist Securities | Reiterates | Buy | $156 |
| Oct 30 | Keybanc | Maintains | Overweight | $150 |
| Oct 29 | Barclays | Maintains | Overweight | $151 |
Across the four most recent analyst notes published on Encompass Health over the past 30 days, price targets range from $150 to $156.
Explore more price target data and ratings for Encompass Health on the Forecasts tab, and track all previous and future analyst recommendations in the dedicated News Flow.
Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.
Read the full article
Get unlimited access to analyst updates and every other article on TradingView.